Steven Cohen Akebia Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $1.75 Million - $9.6 Million	-734,028 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$6.67 - $13.58 $8.27 Million - $16.8 Million	-1,240,292 Reduced 62.82%	734,028 $9.97 Million
Q1 2020 May 15, 2020	SELL	$4.1 - $10.24 $1.57 Million - $3.93 Million	-383,780 Reduced 16.27%	1,974,320 $15 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $1.85 Million - $3.94 Million	585,800 Added 33.05%	2,358,100 $14.9 Million
Q3 2019 Nov 15, 2019	BUY	$3.55 - $5.4 $528,595 - $804,060	148,900 Added 9.17%	1,772,300 $6.95 Million

Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $4.59 Million - $9.01 Million	1,119,027 Added 221.86%	1,623,400 $7.86 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $1.11 Million - $1.89 Million	206,161 Added 69.13%	504,373 $2.79 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $2.22 Million - $3.18 Million	298,212 New	298,212 $2.63 Million
Q2 2018 Aug 14, 2018	SELL	$9.15 - $11.34 $1.78 Million - $2.2 Million	-194,150 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$9.53 - $15.68 $1.85 Million - $3.04 Million	194,150 New	194,150 $1.85 Million

127

56.7M

937K

743K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $176M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.